Managing Intellectual Property

House of Lords backs Lundbeck patent (subscribers only)

25 February 2009

James Nurton, London

The UK’s House of Lords has upheld a controversial second-generation patent that had been invalidated at first instance for insufficiency, in a decision that will be welcomed by the pharmaceutical industry

In a unanimous decision, the five Lords (the UK’s highest court) ruled on February 25 that Lundbeck’s patent for escitalopram – branded as Lexapro, Cipralex or Cipramil as well as other names – is valid. The drug is the world’s biggest selling antidepressant by volume.

The validity of the European patent, which has a priority date of June 14 1988, had been challenged by three generic manufacturers – Generics (UK), Arrow Generics and Teva.

At first instance, Mr Justice Kitchin rejected their attacks of lack of novelty and obviousness. But he agreed with their insufficiency claim.

The patent claimed escitalopram as a product, though the invention itself was essentially just one means of making it.

Citing the House of Lords 1997 decision in Biogen v Medeva, Kitchin said the technical contribution of the patent was not to find a new product, but rather...



Only subscribers have complete access to Managing IP Magazine, log in or subscribe now.

Alternatively take a free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).

Subscribe Now

This article is available to subscribers. Please click subscribe to read the rest of the article.

Subscribe

Take a free trial

Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.

Take a free trial


February 2012

Patent survey 2012

Managing IP ranks the leading patent firms around the world



Most read articles

Poll

Will the new post grant and inter partes review proceedings result in more litigators practising pro hac vice before the USPTO?







Supplements